Sol-Gel completes patient follow-up in Gorlin syndrome Phase 3 trialSep 17Clinical readoutpatidegibSol-Gel Technologies Ltd.
Sol-Gel reports Q2 2026 results, SGT-610 Phase 3 readout on track for late NovemberAug 20Clinical readoutpatidegibSol-Gel Technologies Ltd.
Sol-Gel posts terminated Phase 2 patidegib gel trial results; 2 of 47 had serious adverse eventsJul 21Trial updatepatidegibSol-Gel Technologies Ltd.
Sign inSign in